Abstract:Objective To evaluate the efficacy and safety of the combination therapy of Irinotecan and Cisplatin as a second-line regimen for patients with advanced gastric cancer.Methods Twenty-eight patients with advanced gastric cancer were verified with histopathology and iconography,who received irinotecan and Cisplatin as a second-line regimen were evaluated.The combination therapy consisted of intravenous administration of irinotecan 70 mg/m2during 1 h,on day 1and 8,followed by Cisplatin 70 mg/m2 during 2 h on day 1,and repeated every 3 weeks.Efficacy was evaluated every 6 weeks(2 circles) according to RECIST standard,toxicities were assessed based on CTCAE3.0 after each circle.The follow up period was 30 months,and the survival analyses was all estimated using the Kaplan-Meier method.Results All of the 28 patients were assessable for response.In the study,1 patient experienced complete remission(CR)(3.6%),11 patients partial remission(PR)(39.3%),6 patients stable disease(SD)(21.4%),and 10 patients showed progressive disease(PD)(35.7%).The overall response rate was 42.9%(CR+PR).The median time to disease progress(TTP) was 5 months(95% confidence interval ,range 3.0~24 months),and the median overall survival time(OS) was 8 months(95% confidence interval ,range 5.0~30.0 months).3~4 grade hematological adverse events were: neutropenia 35.7%,thrombocytopenia 25%,anemia 14.3%.3~4 grade nonhematological adverse events were: nausea /vomitting 35.7%;diarrhea 17.8%.Furthermore,no treatment-related deaths were observed.Conclusion Combination therapy of irinotecan with nedaplatin in advanced gastric cancer as a second-line regimen is effective recently,safe and well tolerated.

Combined Chemotherapy with Lrinotecan and Cisplatin As A Second-line Regimen for Patients with Advanced Gastric Cancer